NASDAQ:VPHM - Shire Viropharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week Range$23.13 - $50.01
VolumeN/A
Average VolumeN/A
Market Capitalization$3.30 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.14

About Shire Viropharma (NASDAQ:VPHM)

Shire Viropharma logoViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.

Receive VPHM News and Ratings via Email

Sign-up to receive the latest news and ratings for VPHM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:VPHM
CUSIP92824110
Phone+1-610-4587300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares65,860,000

Shire Viropharma (NASDAQ:VPHM) Frequently Asked Questions

What is Shire Viropharma's stock symbol?

Shire Viropharma trades on the NASDAQ under the ticker symbol "VPHM."

How were Shire Viropharma's earnings last quarter?

Shire Viropharma Inc (NASDAQ:VPHM) released its quarterly earnings data on Thursday, October, 24th. The biotechnology company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.15. The biotechnology company earned $113 million during the quarter, compared to the consensus estimate of $113.35 million. The business's revenue was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS. View Shire Viropharma's Earnings History.

Has Shire Viropharma been receiving favorable news coverage?

News headlines about VPHM stock have trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Shire Viropharma earned a daily sentiment score of 0.17 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.43 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of Shire Viropharma?

Shares of VPHM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is Shire Viropharma?

Shire Viropharma has a market capitalization of $3.30 billion.

How can I contact Shire Viropharma?

Shire Viropharma's mailing address is 730 Stockton Dr, EXTON, PA 19341-1171, United States. The biotechnology company can be reached via phone at +1-610-4587300.


MarketBeat Community Rating for Shire Viropharma (VPHM)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  197 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  428
MarketBeat's community ratings are surveys of what our community members think about Shire Viropharma and other stocks. Vote "Outperform" if you believe VPHM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VPHM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Shire Viropharma (NASDAQ:VPHM) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/24/2016 forward)

Earnings

Shire Viropharma (NASDAQ:VPHM) Earnings History and Estimates Chart

Earnings by Quarter for Shire Viropharma (NASDAQ:VPHM)

Shire Viropharma (NASDAQ VPHM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2013Q313$0.05$0.20$113.35 million$113.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.01$0.15$105.06 million$104.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.04$0.15$108.47 million$107.00 millionViewN/AView Earnings Details
2/27/2013Q4 2012$0.03$0.10$103.06 million$106.50 millionViewN/AView Earnings Details
10/25/2012$0.13$0.10ViewN/AView Earnings Details
8/9/2012$0.19$0.09ViewN/AView Earnings Details
5/1/2012$0.42$0.37ViewN/AView Earnings Details
2/28/2012$0.44$0.65ViewN/AView Earnings Details
10/27/2011$0.37$0.56ViewN/AView Earnings Details
7/28/2011$0.41$0.28ViewN/AView Earnings Details
4/28/2011$0.41$0.40ViewN/AView Earnings Details
2/24/2011$0.32$0.43ViewN/AView Earnings Details
10/27/2010Q3 2010$0.31$0.52ViewN/AView Earnings Details
7/28/2010Q2 2010$0.30$0.34ViewN/AView Earnings Details
4/28/2010Q1 2010$0.31$0.29ViewN/AView Earnings Details
2/24/2010Q4 2009$0.24$0.23ViewN/AView Earnings Details
10/28/2009Q3 2009$0.26$0.34ViewN/AView Earnings Details
7/29/2009Q2 2009$0.19$0.20ViewN/AView Earnings Details
4/29/2009Q1 2009$0.15$0.09ViewN/AView Earnings Details
2/24/2009Q4 2008$0.16$0.02ViewN/AView Earnings Details
10/29/2008Q3 2008$0.23$0.33ViewN/AView Earnings Details
7/30/2008Q2 2008$0.26$0.30ViewN/AView Earnings Details
4/30/2008Q1 2008$0.23$0.22ViewN/AView Earnings Details
2/27/2008Q4 2007$0.20$0.25ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Shire Viropharma (NASDAQ:VPHM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Shire Viropharma (NASDAQ VPHM) Insider Trading and Institutional Ownership History

Insider Trading History for Shire Viropharma (NASDAQ:VPHM)

Shire Viropharma (NASDAQ VPHM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/24/2012Colin Md BroomVPSell17,500$22.53$394,275.00View SEC Filing  
12/3/2012John Peter Wolf IIIVPSell18,000$24.85$447,300.00View SEC Filing  
12/3/2012William D Md ClaypoolDirectorSell10,000$24.80$248,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Shire Viropharma (NASDAQ VPHM) News Headlines

Source:
DateHeadline
Reviewing Senomyx (SNMX) and Shire Viropharma (VPHM)Reviewing Senomyx (SNMX) and Shire Viropharma (VPHM)
www.americanbankingnews.com - March 4 at 7:08 PM
Critical Review: Adamis Pharmaceuticals Corporation (ADMP) and Shire Viropharma (VPHM)Critical Review: Adamis Pharmaceuticals Corporation (ADMP) and Shire Viropharma (VPHM)
www.americanbankingnews.com - October 14 at 10:46 AM
Contrasting Shire Viropharma (VPHM) & BioLife Solutions (BLFS)Contrasting Shire Viropharma (VPHM) & BioLife Solutions (BLFS)
www.americanbankingnews.com - September 12 at 2:26 AM
Comparing Eli Lilly and (LLY) & Shire Viropharma (VPHM)Comparing Eli Lilly and (LLY) & Shire Viropharma (VPHM)
www.americanbankingnews.com - September 9 at 6:22 PM
Promising New Treatment Emerges For Deadly C. difficile ColitisPromising New Treatment Emerges For Deadly C. difficile Colitis
www.forbes.com - May 5 at 11:00 AM

SEC Filings

Shire Viropharma (NASDAQ:VPHM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Shire Viropharma (NASDAQ:VPHM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Shire Viropharma (NASDAQ VPHM) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.